Eliquis — Revenues:
Pfizer Eliquis — Revenues: increased by 7.2% to $2.17B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 12.6%, from $1.92B to $2.17B. Over 4 years (FY 2021 to FY 2025), Eliquis — Revenues: shows an upward trend with a 7.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates strong market adoption and effective commercialization of the drug, while a decrease may signal increased competition, patent expiration, or shifts in clinical guidelines.
Detailed definition
This metric represents the total gross sales generated by a specific pharmaceutical product line within the company's ca...
Peer comparison
Comparable to product-level revenue reporting in other major pharmaceutical companies, often benchmarked against competing therapies in the same therapeutic class.
pfe_segment_eliquis_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.48B | $1.35B | $1.50B | $1.79B | $1.75B | $1.46B | $1.48B | $1.87B | $1.76B | $1.50B | $1.61B | $2.04B | $1.88B | $1.62B | $1.83B | $1.92B | $2.00B | $2.02B | $2.02B | $2.17B |
| QoQ Change | — | -9.1% | +11.4% | +19.5% | -2.7% | -16.1% | +1.0% | +26.7% | -6.0% | -15.0% | +7.6% | +26.6% | -8.0% | -13.9% | +13.3% | +5.0% | +4.2% | +0.6% | +0.2% | +7.2% |
| YoY Change | — | — | — | — | +17.8% | +8.8% | -1.4% | +4.5% | +1.0% | +2.3% | +9.0% | +8.9% | +6.5% | +7.9% | +13.6% | -5.7% | +6.7% | +24.6% | +10.3% | +12.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Pfizer's eliquis — revenues:?
- Pfizer (PFE) reported eliquis — revenues: of $2.17B in Q1 2026.
- How has Pfizer's eliquis — revenues: changed year-over-year?
- Pfizer's eliquis — revenues: increased by 12.6% year-over-year, from $1.92B to $2.17B.
- What is the long-term trend for Pfizer's eliquis — revenues:?
- Over 4 years (2021 to 2025), Pfizer's eliquis — revenues: has grown at a 7.5% compound annual growth rate (CAGR), from $5.97B to $7.96B.
- What does eliquis — revenues: mean?
- The total revenue generated from the sales of a specific pharmaceutical product.